1. Home
  2. Stocks
  3. Aartidrugs Share Price
  • Chart
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Aarti Drugs

    Small Cap
    ₹526.7
    + 1.1 (0.21%)
    • Advice
    • Hold
    27 July, 2024 07:07 BSE: 524348 NSE: AARTIDRUGS ISIN: INE767A01016

    Start SIP in Aarti Drugs

    Start SIP

    Aarti Drugs Performance

    Day Range

    • Low 525
    • High 533
    ₹ 526

    52 Week Range

    • Low 431
    • High 625
    ₹ 526
    • Open Price527
    • Previous Close526
    • Volume83301

    Aarti Drugs Share Price

    • Over 1 Month + 2.69%
    • Over 3 Month + 4.47%
    • Over 6 Month + 4.39%
    • Over 1 Year -9.42%

    Aarti Drugs Key Statistics

    P/E Ratio 30.9
    PEG Ratio -2.5
    Market Cap Cr
    Price to Book Ratio 3.8
    EPS 15.4
    Dividend 0.2
    Relative Strength Index 51.21
    Money Flow Index 41.86
    MACD Signal 5.22
    Average True Range 15.75
    Aarti Drugs Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 493560538578592696
    Operating Expenses Qtr Cr 439490478512520608
    Operating Profit Qtr Cr 546960657289
    Depreciation Qtr Cr 121212121212
    Interest Qtr Cr 787888
    Tax Qtr Cr 81411121416
    Net Profit Qtr Cr 273632354053
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 2,2712,500
    Operating Expenses Annual Cr 2,0012,216
    Operating Profit Annual in Cr 266282
    Depreciation Cr 4847
    Interest Annual Cr 3033
    Tax Annual Cr 5152
    Net Profit Annual Cr 142153
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 337162
    Cash from Investing Activity Annual Cr -187-131
    Cash from Financing Annual Activity Cr -149-31
    Net Cash Flow Annual Cr 11
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 1,1751,114
    Fixed Assets Annual Cr 942795
    Total Non Current Assets Annual Cr 991846
    Total Current Assets Annual Cr 1,1811,350
    Total Assets Annual Cr 2,1722,195
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 128120
    ROE Annual % 1214
    ROCE Annual % 1517
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1211
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 555620606642661742
    Operating Expenses Qtr Cr 490534536565577649
    Operating Profit Qtr Cr 658670768494
    Depreciation Qtr Cr 131413131313
    Interest Qtr Cr 998899
    Tax Qtr Cr 111715171617
    Net Profit Qtr Cr 334737404856
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 2,5332,718
    Operating Expenses Annual Cr 2,2122,410
    Operating Profit Annual in Cr 316306
    Depreciation Cr 5150
    Interest Annual Cr 3433
    Tax Annual Cr 6458
    Net Profit Annual Cr 172166
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 359134
    Cash from Investing Activity Annual Cr -224-164
    Cash from Financing Annual Activity Cr -13617
    Net Cash Flow Annual Cr -1-13
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 1,2821,192
    Fixed Assets Annual Cr 1,070887
    Total Non Current Assets Annual Cr 1,112929
    Total Current Assets Annual Cr 1,3211,492
    Total Assets Annual Cr 2,4322,421
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 139129
    ROE Annual % 1314
    ROCE Annual % 1617
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1311
    Invest in Aarti Drugs

    Aarti Drugs Technicals

    EMA & SMA

    Current Price
    ₹526.7
    + 1.1 (0.21%)
    pointer
    • Bullish Moving Average
    • ___
    • 10
    • Bearish Moving Average
    • ___
    • 6
    • 20 Day
    • ₹526.89
    • 50 Day
    • ₹516.84
    • 100 Day
    • ₹508.64
    • 200 Day
    • ₹502.51
    • 20 Day
    • ₹532.13
    • 50 Day
    • ₹513.13
    • 100 Day
    • ₹496.18
    • 200 Day
    • ₹500.08

    Aarti Drugs Resistance and Support

    PIVOT
    ₹528.07
    Resistance
    First Resistance 531.13
    Second Resistance 535.57
    Third Resistance 538.63
    RSI 51.21
    MFI 41.86
    MACD Single Line 5.22
    MACD 2.93
    Support
    First Support 523.63
    Second Support 520.57
    Third Supoort 516.13

    Aarti Drugs Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 86,293 3,860,749 44.74
    Week 95,390 4,048,360 42.44
    1 Month 205,284 8,738,948 42.57
    6 Month 214,306 9,622,323 44.9

    Aarti Drugs Result Highlights

    Aarti Drugs Synopsis

    NSE-Medical-Diversified

    Aarti Drugs Ltd is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 2266.91 Cr. and Equity Capital is Rs. 91.94 Cr. for the Year ended 31/03/2024. Aarti Drugs Ltd. is a Public Limited Listed company incorporated on 28/09/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L37060MH1984PLC055433 and registration number is 055433.
    Market Cap 4,842
    Sales 2,168
    Shares in Float 4.05
    No of funds 83
    Yield 0.19
    Book Value 4.12
    U/D Vol ratio 2.7
    LTDebt / Equity 20
    Alpha -0.13
    Beta 0.81

    Aarti Drugs Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 55.67%57.13%57.47%58.56%
    Mutual Funds 5.7%5.08%5.18%5.22%
    Insurance Companies 0.08%0.08%0.08%0.1%
    Foreign Portfolio Investors 2.95%2.56%2.1%2.33%
    Financial Institutions/ Banks
    Individual Investors 24.76%25.12%25.84%24.65%
    Others 10.84%10.03%9.33%9.14%

    Aarti Drugs Management

    Name Designation
    Mr. Chandrakant V Gogri Chairman Emeritus
    Mr. Prakash M Patil Chairman & M.D & CEO
    Mr. Rashesh C Gogri Managing Director
    Mr. Harshit M Savla Joint Managing Director
    Mr. Harit P Shah Executive Director
    Mr. Uday M Patil Executive Director
    Mrs. Neha R Gada Independent Director
    CA. Navin C Shah Independent Director
    Dr. Krishnacharya G Akamanchi Independent Director
    Prof. Bhaskar N Thorat Independent Director
    Mrs. Priti P Savla Independent Director
    Mr. Ankit V Paleja Independent Director
    Mr. Narendra J Salvi Non Executive Director

    Aarti Drugs Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Aarti Drugs Corporate Action

    Date Purpose Remarks
    2024-07-26 Quarterly Results
    2024-05-03 Audited Results
    2024-01-24 Quarterly Results & Interim Dividend
    2023-10-19 Quarterly Results
    2023-07-21 Quarterly Results & Buy Back
    Date Purpose Remarks
    2024-02-06 INTERIM Rs.1.00 per share(10%)Interim Dividend
    2023-02-08 INTERIM Rs.1.00 per share(10%)Interim Dividend
    2022-02-10 INTERIM Rs.1.00 per share(10%)Interim Dividend

    Aarti Drugs MF Shareholding

    Name Amount(cr)
    DSP Small Cap Fund Regular Plan Growth 15,244
    DSP Healthcare Fund Regular Growth 2,479
    Motilal Oswal Nifty Microcap 250 Index Fund Regular Growth 1,168
    DSP Value Fund Regular Plan Growth 843

    Aarti Drugs FAQs

    What is Share Price of Aarti Drugs ?

    Aarti Drugs share price is ₹526 As on 27 July, 2024 | 06:53

    What is the Market Cap of Aarti Drugs ?

    The Market Cap of Aarti Drugs is ₹4842.2 Cr As on 27 July, 2024 | 06:53

    What is the P/E ratio of Aarti Drugs ?

    The P/E ratio of Aarti Drugs is 30.9 As on 27 July, 2024 | 06:53

    What is the PB ratio of Aarti Drugs ?

    The PB ratio of Aarti Drugs is 3.8 As on 27 July, 2024 | 06:53

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 29/07/2024 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of ₹10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.